Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science
REDWOOD CITY, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Christopher J. Morrison, Ph.D. joined the company as vice president, process development, reporting into Adverum’s chief technology officer Angela Thedinga.
“Chris brings a wealth of AAV gene therapy experience and will lead the scale-up of our commercial manufacturing process for ADVM-022,” said Angela Thedinga, chief technology officer of Adverum. “We are delighted to welcome Chris at this exciting and pivotal time as we continue to execute on our strategy to deliver ADVM-022 to patients.”
Christopher J. Morrison, Ph.D. has 10 years of pharmaceutical industry experience and has a background in gene therapy, recombinant adeno-associated viral vector (rAAV) process development, and clinical manufacturing. Most recently, he worked with ApicBio Therapeutics as senior director, biopharmaceutical development. Previously, he worked with Gemini Therapeutics as senior director, CMC operations. Earlier, he worked with Voyager Therapeutics, serving as director, biopharmaceutical development, promoted from associate director, head of process development. At Voyager, he directed the development and implementation of Phase 1/2 and Phase 3 manufacturing processes for multiple rAAV products of assorted serotypes and genomic construct produced by Sf9-Baculovirus or HEK293 transient transfection-based production systems. Dr. Morrison began his industry career at Pfizer as a senior scientist before being promoted to principal scientist, responsible for downstream purificaion processes for a broad range of biological molecules.
Dr. Morrison earned a Doctorate of Philosophy in Chemical and Biological Engineering from Rensselaer Polytechnic Institute and a Bachelor of Science in Chemical Engineering from the University of Wisconsin at Madison.
On September 14, 2020, the company granted Dr. Morrison a stock option to purchase 100,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to his entering into employment with Adverum. The option has a per share exercise price equal to the closing sales price of Adverum’s common stock on the Nasdaq Stock Market on the grant date, and will vest over four years, subject to his continued service with Adverum.
About Adverum Biotechnologies
Investor and Media Inquiries: Investors: Myesha Lacy Adverum Biotechnologies, Inc. firstname.lastname@example.org 1-650-649-1257 Media: Cherilyn Cecchini, M.D. LifeSci Communications email@example.com 1-646-876-5196
How to Strategically Leverage New Connectivity Options